智通财经APP讯，ST华闻(000793.SZ)公告，公司收到海南省海口市中级人民法院送达的《民事裁定 书》，裁定受理公司债权人三亚凯利投资有限公司(简称"三亚凯利")对公司的重整申请。因海口中院依 法裁定受理债权人对公司的重整申请，公司股票交易将于2026年3月2日被实施退市风险警示，股票简称 变更为"*ST华闻"，证券代码仍为"000793"，股票日涨跌幅限制仍为5%。公司股票将于2026年2月27日 开市起停牌一天，自2026年3月2日开市起复牌。 ...

因海口中院依法裁定受理债权人对公司的重整申请，根据《深圳证券交易所股票上市规则》第9.4.1条第 （九）项的规定，公司股票交易将于2026年3月2日被实施退市风险警示，股票简称变更为"*ST华闻"， 证券代码仍为"000793"，股票日涨跌幅限制仍为5%。根据《深圳证券交易所股票上市规则》第9.4.9条 的规定，公司股票将于2026年2月27日开市起停牌一天，自2026年3月2日开市起复牌。 格隆汇2月26日丨ST华闻（维权）(000793.SZ)公布，收到海南省海口市中级人民法院（简称"海口中 院"或"法院"）送达的《民事裁定书》[（2024）琼01破申70号]，裁定受理公司债权人三亚凯利投资有限 公司（简称"三亚凯利"）对公司的重整申请。 ...

格隆汇2月24日丨ST华闻(000793.SZ)在投资者互动平台表示，公司目前未依托seedance技术开展业务。 ...

智通财经APP讯，ST人福(600079.SH)发布公告，本次发行的发行对象为公司控股股东招商生科，发行 对象以人民币现金方式认购公司本次发行的股票，本次发行构成关联交易。本次发行的募集资金总额为 不低于人民币30亿元(含本数)且不超过人民币35亿元(含本数)，扣除相关发行费用后的募集资金净额拟 用于创新药研发项目-子公司宜昌人福项目、创新药研发项目-总部研究院项目、两性健康及复杂制剂制 造基地建设项目、数智化建设项目以及补充流动资金。 ...

格隆汇2月24日丨ST人福（维权）(600079.SH)公布2026年度向特定对象发行A股股票预案，本次发行的 发行对象为公司控股股东招商生科，发行对象以人民币现金方式认购公司本次发行的股票，本次发行构 成关联交易。本次发行的募集资金总额为不低于人民币300,000万元（含本数）且不超过人民币350,000 万元（含本数），扣除相关发行费用后的募集资金净额拟用于创新药研发项目－子公司宜昌人福项目、 创新药研发项目－总部研究院项目、两性健康及复杂制剂制造基地建设项目、数智化建设项目以及补充 流动资金。 上个马年沪指涨近60%！新年新福利来了，炒股排面要拉满，新号启幸运>> ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 世紀建業(集團)有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00079 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.2 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.2 | HKD | | 400,000,000 | 本月底法定/註冊 ...

Group 1: Market Overview - The A-share market experienced slight fluctuations on January 7, with the Shanghai Composite Index showing resilience by closing in the green, marking a rare occurrence of 14 consecutive bullish candles [1][3] - The overall market saw a moderate increase in trading volume, reaching 2.88 trillion yuan, with a higher number of declining stocks compared to advancing ones [1][3] Group 2: Sector Performance - The chip and fishery sectors showed significant activity, with the fishery index surging over 4% and stocks like Zhongshui Fishery (000798) hitting the daily limit [3][4] - Other active sectors included hotels and restaurants, while oil and gas extraction, aerospace equipment, and brain engineering faced declines [3] Group 3: Fund Flows - Major inflows were observed in the power and machinery sectors, with over 90 billion yuan in net inflows, while the computer sector saw a net outflow exceeding 40 billion yuan [3] - The market sentiment is influenced by expectations of credit expansion and policy support, particularly benefiting new economic forces in advanced manufacturing and overseas enterprises [3][4] Group 4: Regulatory Impact - The Chinese Ministry of Commerce announced strict export controls on dual-use items to Japan, which may impact the seafood market dynamics, as Japan is a significant export destination for Chinese seafood [6] - The announcement reflects ongoing geopolitical tensions and could lead to increased domestic demand for Chinese seafood products [6] Group 5: Chip Sector Insights - The chip sector has continued to strengthen, with multiple stocks hitting daily limits, driven by a severe shortage of memory chips reported by Samsung [7] - The trend towards supply chain security and domestic control is expected to persist, with advancements in chip technology and production processes being critical for future growth [7]

Market Overview - The A-share market experienced slight fluctuations on January 7, with the Shanghai Composite Index showing resilience by closing in the green, marking a rare occurrence of 14 consecutive positive daily candles [2] - The overall market saw a trading volume increase to 2.88 trillion yuan, with more stocks declining than advancing [2] Sector Performance - The chip and fishery sectors showed significant activity, with the fishery index rising over 4% and trading volume doubling compared to the previous day [3] - Major inflows of capital were observed in the power equipment and machinery sectors, each receiving over 9 billion yuan, while the computer sector faced a net outflow exceeding 4 billion yuan [2] Investment Outlook - Zhongyuan Securities anticipates a stable upward trend for the Shanghai Composite Index, driven by positive changes in corporate profit structures and new economic forces [3] - Guosheng Securities highlights a clear direction for domestic and international easing policies, suggesting a favorable mid-term trend for the market [3] Regulatory Developments - The Ministry of Commerce of China announced a ban on the export of dual-use items to Japan for military purposes, which may impact the seafood market dynamics [6] - Japan's seafood exports to China accounted for 22.5% of its total seafood exports, indicating a significant market relationship that could be affected by regulatory changes [7] Chip Sector Insights - The chip sector continues to perform strongly, with several companies experiencing significant stock price increases, including a number of stocks hitting the 20% and 30% daily limit up [7] - Samsung reported an unprecedented shortage of memory chips, which is expected to impact prices of end products like smartphones [7]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 世紀建業(集團)有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00079 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.2 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.2 | HKD | | 400,000,000 | 本 ...

Core Viewpoint - ST Renfu (600079.SH) has received approval from the National Medical Products Administration for its drug HW221043, which is intended for the treatment of advanced solid tumors and is a new molecular entity developed by the company [1] Group 1: Drug Development - HW221043 is a new molecular compound developed independently by the company [1] - There are currently no similar drugs approved for market use domestically or internationally [1] - The total research and development investment for HW221043 has reached approximately 24 million RMB [1]